EDMONTON, May 16 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced that Dr. Mark Redmond will be presenting at the BioFinance 2005 conference to be held in Toronto, Ontario, May 17- 19, 2005. The conference features approximately 100 life sciences companies from Canada, United States, and Europe. Ceapro's presentation will take place at 4:00 p.m. EDT on Wednesday, May 18th; a copy of the slides will be posted on the Ceapro website. "This is an important opportunity to introduce Ceapro to a wider financial audience and generate greater exposure in the context of biotechnology investments," said Dr. Mark Redmond, Ceapro's President and CEO. "Our presentation will feature CeaProve(TM) as a new and important innovation in the field of diabetes diagnostics and Ceapro's ability to deliver products to market successfully, as demonstrated by our active ingredients and veterinary therapeutic products business." BioFinance 2005 (www.biofinance.ca) is the Life Science industry's leading investor conference. The meeting brings together key players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives, and experts from the scientific and medical communities in Canada, the United States, Europe, and Asia. 2004 Annual and Special Meeting Ceapro's annual and special meeting of shareholders will be held in Edmonton, Alberta on Wednesday, June 1, 2005, at Lister Centre, University of Alberta, at 3:00 p.m. MDT. About Ceapro Inc. Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.30. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro to present at BioFinance conference
Earlier from Ceapro
- Ceapro announces 2004 financial results
- Ceapro receives further investment from AVAC Ltd.
- Ceapro announces new Controller
- Ceapro rebrands patented diabetes technology as CeaProve(TM)
Later from Ceapro
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
- Ceapro announces officer appointment
- Ceapro Announces Granting of Stock Options
- Ceapro announces 2005 second quarter financial results
- Ceapro announces adoption of CeaProve(TM) in global Glycemic Index study
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro